OR
$13.63
-0.22
(-1.59%)
As of Oct 22, 2026, 9:29 PM EDT
Price history
Oric Pharmaceuticals Inc (ORIC) is trading down at $13.63 (-1.59%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: April 24, 2020 · $16.00 offering · NASDAQ · View IPO details →
Oric Pharmaceuticals Inc net income history (FY2018–FY2025)
Net income
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$22.4M | −$28.6M | −$74.2M | −$78.9M | −$91.8M | −$110.8M | −$142.9M | −$143.0M |
| Net income | −$21.4M | −$26.9M | −$73.7M | −$78.7M | −$89.1M | −$100.7M | −$127.8M | −$129.5M |
| EPS (diluted) | −$12.32 | −$14.15 | −$3.36 | −$2.07 | −$2.25 | −$1.96 | −$1.83 | −$1.47 |
| Balance sheet | ||||||||
| Cash and equivalents | $42.6M | $89.2M | $78.4M | $226.0M | $66.8M | $23.4M | $59.4M | $45.7M |
| Total assets | — | $94.1M | $299.0M | $298.6M | $247.2M | $252.0M | $274.1M | $408.9M |
| Total liabilities | — | $6.12M | $9.22M | $25.7M | $24.8M | $27.9M | $31.0M | $24.5M |
| Long-term debt | — | — | $600.0K | $10.5M | — | — | — | — |
| Shareholders' equity | −$64.4M | −$90.1M | $289.8M | $273.0M | $222.4M | $224.1M | $243.1M | $384.4M |
| Cash flow | ||||||||
| Operating cash flow | −$20.7M | −$23.5M | −$45.3M | −$59.5M | −$75.1M | −$85.7M | −$112.7M | −$111.0M |
| Capital expenditure | $525.0K | $768.0K | $667.0K | $939.0K | $2.08M | $849.0K | $1.19M | $712.0K |
| Free cash flow | −$21.2M | −$24.3M | −$45.9M | −$60.5M | −$77.2M | −$86.5M | −$113.8M | −$111.7M |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$38.3M | −$39.6M | −$32.7M | −$39.1M | −$36.7M | −$34.6M | −$39.6M | −$45.3M |
| Net income | −$34.6M | −$36.3M | −$30.0M | −$36.4M | −$32.6M | −$30.5M | −$35.8M | −$41.5M |
| EPS (diluted) | −$0.49 | −$0.52 | −$0.42 | −$0.47 | −$0.33 | −$0.25 | −$0.34 | −$0.38 |
| Balance sheet | ||||||||
| Cash and equivalents | $44.2M | $59.4M | $49.3M | $75.9M | $49.7M | $45.7M | $56.4M | $37.5M |
| Total assets | $302.1M | $274.1M | $242.9M | $346.9M | $431.2M | $408.9M | $436.8M | $404.7M |
| Total liabilities | $28.1M | $31.0M | $23.1M | $22.9M | $24.3M | $24.5M | $21.2M | $23.4M |
| Shareholders' equity | $274.0M | $243.1M | $219.7M | $324.0M | $406.9M | $384.4M | $415.6M | $381.3M |
| Cash flow | ||||||||
| Operating cash flow | −$28.8M | −$28.1M | −$32.5M | −$30.8M | −$25.1M | −$22.5M | −$32.4M | −$31.6M |
| Capital expenditure | $418.0K | $219.0K | $387.0K | $63.0K | $35.0K | $227.0K | $2.00K | $356.0K |
| Free cash flow | −$29.2M | −$28.3M | −$32.9M | −$30.9M | −$25.1M | −$22.7M | −$32.4M | −$32.0M |
From Oric Pharmaceuticals Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Oric Pharmaceuticals Inc
- Headquarters
- South San Francisco, California From SEC filings, Oct 2026
Recent News (2)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International